Following the publication of the WHO CNS 4 classification guideline in 2016, researchers have identified several specific molecular markers including IDH1/2, EGFR, TERT, and MGMT that are relevant for survival and response to treatment in patients with CNS tumors.8, 9, 10, 11. Here, IDH1 is linked to central nervous system neoplasm.